1. Introduction {#sec1}
===============

Diabetes mellitus is considered an epidemic disease in the gulf countries. Its prevalence in Saudi Arabia is considered to be the highest in the world affecting 23--30% of adults above 30 years of age \[[@B1]--[@B3]\]. Diabetes mellitus is the most common endocrine problem encountered in family medicine practice \[[@B4]\]. Most Saudi citizens have direct access to primary care and most chronic diseases, including diabetes mellitus, are managed at this level \[[@B4]\]. The cost of prescriptions has been estimated to account for 30--40% of the direct cost of diabetes. A substantial increase in the cost of medication for diabetes is observed with the increased use of new antidiabetic and cardiovascular medications and use of the evidence based guidelines \[[@B6]--[@B9]\].

Al Maatouq Manual of Diabetes Practice indicates that the therapeutic regimen for hyperglycemia in type 2 diabetes includes the oral antidiabetic agents, insulin, or a combination of both. Metformin is the initial recommended drug for type 2 diabetes \[[@B10]--[@B13]\]. New drugs for hyperglycemia, such as incretins, are promising \[[@B14], [@B15]\]. Glycosylated hemoglobin A1c (HbA1c) is the test most widely used for assessment of blood glucose control. The current target level is approximately 7% with consideration of individualized care \[[@B13], [@B14]\].

Diabetes is commonly associated with risk factors for cardiovascular disease (CVD). Standard diabetes care recommends drug therapy for control of blood pressure, dyslipidemia, and assessment for the need for antiplatelets therapy \[[@B13], [@B16]--[@B19]\]. Hypertension affects 60% of the population with type 2 diabetes. The high prevalence of undiagnosed nephropathy may still favor recommendations for the use of inhibitors of the renin-angiotensin system (RAS) as first-line hypertension therapy in people with diabetes \[[@B17]\].

Dyslipidemia is highly prevalent among the diabetic population \[[@B19]\].

Low density lipoproteins (LDL) cholesterol-targeted statin therapy remains the preferred strategy for this condition \[[@B9]\]. Antiplatelet therapy for patients with previous CVD is highly recommended for secondary prevention. The current recommendation for primary prevention of CVD has been changed to be selective to women above 60 years of age with one additional risk factor \[[@B13], [@B20]\].

The objective of this study was to investigate the prescription practice for diabetic management of a female Saudi population and to evaluate the utilization of the medications in relation to the international guidelines.

2. Methodology {#sec2}
==============

This study is a cross-sectional investigation of female patients with diabetes seen in the Al Imam Medical Complex from January to May 2012. The complex is an ambulatory care service belonging to the medical college at Al Imam Mohammed Islamic University in Riyadh, Saudi Arabia. It serves the students and the staff of the university and their dependents. It is a multispecialty center attached to the Ministry of Health Hospitals. It has two sections based on gender for both the staff and the clients.

According to the pharmacy registry, there are approximately 350 women with diabetes at this centre. The female cases are followed up within the primary care and family medicine clinics. The medical center has most of the facilities needed for outpatient diabetes management including manpower, basic laboratory tests, and drugs.

Consecutive samples of 160 cases who were on antidiabetic drugs and visited the center during the period of the study were included. Patients who do not have diabetes and taking metformin, such as cases with polycystic ovary syndrome or obesity, were excluded. A data collection form was designed for the purpose of the study. It contained information on the patient\'s demographics, smoking history, clinical data, the comorbidity, current drug history related to diabetes care, and recent laboratory data. The data were collected by reviewing the last visit in the medical records during the period of the study. The subject\'s drug history was obtained from the medical records and chronic drug registry of the pharmacy.

The data was analyzed using a statistical package for social science, SPSS version 20. The frequency and percentage were estimated for all variables including age, history of hypertension, hyperlipidemia, smoking, and diabetic complications. Blood pressure, body mass index (BMI) values, drug or drug class names in the last visit, HbA1c in the last six months, lipid profile, creatinine level, and urine test for albuminuria in the last year were recorded in the form. Subclassification for the data categories including the age group every 10 years, uncontrolled systolic and diastolic blood pressure, BMI classes, HbA1c above 8%, and high lipid profile levels per diabetes care standard was done. The mean and standard deviation were calculated for numerical variables. Chi-standard test was calculated for the prescription practice and *P* value ≤0.05 was considered significant. The missing data was analyzed with consideration in the percentages and the discussion.

3. Results {#sec3}
==========

The study enrolled 160 women with diabetes. Their clinical profiles are presented in [Table 1](#tab1){ref-type="table"}. The mean (standard deviation (SD)) age of the subjects was 53.7 (11.76) years. The majority of the population (82.4%) were older than 40 years and most (82.5%) were Saudi. There was a lack of documentation of smoking history for most of the subjects (76.3%).

A considerable proportion of cases had comorbidity including hypertension (49.4%), hyperlipidemia (45.0%), and thyroid disorders (14.4%). Less than 5% of the subjects had documented diabetic complications in their medical records.

All the subjects had a blood pressure measurement on their last visit. Mean (SD) systolic and diastolic blood pressure were 118.4 (37.9) mmHg and 69.8 (22.7) mmHg, respectively. Forty percent of cases had blood pressure readings above the recommended level (130 mmHg systolic and 80 mmHg diastolic). This percent dropped to 33% when considering the recent change in target blood pressure (140 mmHg systolic). BMI was reported for only 63.1% the subjects (101 of the 160 participants), and the mean (SD) was 33.7 (5.7) kg/m². Obesity was seen in 80.0% of the cases for whom BMI was available in the medical record.

HbA1c testing was found among 69% of the studied population with a mean (SD) value of 6.6% (2.1). [Figure 1](#fig1){ref-type="fig"} shows the distribution of HbA1c in subjects and indicates that most of the subjects had good glycemic control. The lipid profile was available for two-thirds of the population for total cholesterol and triglyceride levels in the last year. LDL tests were not available for 42% of the samples. The mean (SD) for the lipid profile was cholesterol 4.8 (0.9) mmol/l, triglyceride 1.7 (1.3) mmol/l, LDL 3.1 (1.3) mmol/l, and HDL 1.2 (0.3) mmol/l. Significant proportions of patients had suboptimally treated dyslipidemia based on the recommended guidelines \[[@B13]\]. Many medical records lacked the creatinine test (56%) or assessment of proteinuria (76%) in the last year. The majority of cases who were assessed for nephropathy had normal results.

[Table 2](#tab2){ref-type="table"} shows the pattern of prescriptions for diabetes management. A total of 500 prescriptions were utilized for hyperglycemia, hypertension, hyperlipidemia, and prevention of cardiovascular events for all the subjects. The majority of cases (61%) had three or more prescriptions for diabetes and cardiovascular management where the mean (SD) for the number of prescriptions per subject was 3.0 (1.5). A single medication per subject was observed in only 16% of patients.

Four drug groups were found to be commonly utilized for hyperglycemia, with metformin being the most common medication. More than half of the cases (57%) were on two drugs or more for hyperglycemia. Metformin, plus sulphonylurea, was used in 67 cases (42%) and represented the most common combination. Metformin, plus sulfonylurea, plus pioglitazone was the next most common combination and was seen in 14 cases (8.7%). Insulin monotherapy was used in 9 cases. Compared to monotherapy for treatment of hyperglycemia, combination therapy was significantly associated with the older age group, the presence of diabetes complications and health education visits, and higher HbA1c levels ([Table 3](#tab3){ref-type="table"}).

Four drug groups were found to be commonly utilized for hypertension management. Angiotensin converting enzyme (ACE) inhibitors was the most commonly used antihypertensive agent, followed by angiotensin receptor blockers (ARBs). Most of the subjects (70%) were on combination of two or more drugs. Diuretics, including indapamide or thiazide, were commonly used for combination therapy with equal preference. *β*-Blockers were utilized in diabetes as monotherapy in seven cases. Calcium channel blockers were the least prescribed medication. The association of antihypertensive drugs with clinical characteristics was not significant (*P* ≥ 0.05).

The main drug groups utilized for hyperlipidemia were statins which were significantly associated with the older age group (*P* \< 0.01) and highly significantly associated with higher BMI (*P* \< 0.006). The main drug utilized as an antiplatelet agent was aspirin. The majority of aspirin users were above 50 years of age (*P* \< 0.001), were hypertensive (*P* \< 0.015), and had diabetic complications (*P* \< 0.014). On the other hand, the aspirin use was not significant among the cases with dyslipidemia (*P* \< 0.26).

4. Discussion {#sec4}
=============

The objective of this investigation was to study the prescription practice among female patients with diabetes at the Al Imam Medical Complex. This issue is strongly related to the assessment of risk factors among the patients. Therefore, this study also gives a view on the practice of diabetes care within the primary care.

There was a high prevalence of hypertension and dyslipidemia in our study group that was similar to other gulf countries \[[@B16]\]. On the other hand, diabetic complications were low among the study population. Recording of whether the women in this study were smokers seemed to be neglected or not documented in their medical histories. It should be kept in mind that the population we studied is from an Islamic culture where smoking is forbidden to all. However, the prevalence of smoking among Saudis female population has been reported to range from 1 to 16% \[[@B21]\]. Patient\'s medical histories must be accurate and, in this case, cannot assume that women are nonsmokers, particularly with respect to providing proper diabetes management \[[@B22]\].

Blood pressure was documented for all cases as per international guidelines and is consistent with other published studies \[[@B23]--[@B25]\]. On the other hand, BMI was only documented in 60% of cases which is consistent with other studies \[[@B23], [@B26], [@B27]\].

Weight measurement is recommended as part of diabetes management and needs to be consistently recorded as part of routine nursing practice. Obesity is a coexisting risk factor for patients with diabetes and found to be highly prevalent in subjects in many studies \[[@B2], [@B23], [@B26]\]. Insulin and pioglitazone therapies were used in 28.4% of the population and may have contributed to weight gain in patients taking these medications.

The laboratory tests for assessment of HbA1c, kidney function, and lipid profile were underutilized compared to the recommended guidelines and other studies and similar to a Malaysian study \[[@B21], [@B25], [@B27]\]. This may be related to lack of training of primary care doctors, shortages in the availability of tests, and shared care of the patients with other medical centers. The level of diabetic control among cases with available HbA1c tests (69%) revealed good control among most of them. By comparison, it is similar to that reported for the Canadian population \[[@B23], [@B28]\] and better than that of general Middle East population where the mean HbA1c is 8-9% \[[@B29]\]. Overreduction of HbA1c was observed in this data which may be due to management of hyperglycemia based on spot blood glucose testing. Several possible reasons may account for the good control, including the high level of education of this population, ease of access to health care, shared care with different services, and the availability of most drugs needed for diabetes care. Furthermore, for a prescription to be refilled every two months, patients must see a physician, thereby improving the opportunity for patient care.

The commonly used medications for hyperglycemia control were limited to the available drugs in the services. Metformin was the most commonly prescribed medication for control of hyperglycemia and this follows the international guidelines. This is in contrast to the Middle East data where metformin appears to be less frequently used to initiate antidiabetic therapy \[[@B6], [@B29]\]. Despite knowing the benefits of metformin, approximately 13% of the cases in our study are not being treated with it. The side effects of metformin or the presence of type 1 diabetes may explain these findings. On the other hand, insulin therapy seems to be underutilized in our study and is consistent with previous studies \[[@B9], [@B30], [@B31]\]. Our study was conducted at an ambulatory care facility where most of the cases were not complicated and physicians\' experience with using insulin may not be extensive.

Combination therapy for controlling hyperglycemia seems to be used more among the older age group, in more complicated cases \[[@B32]\] and in patients with higher HbA1c values. There was also marked underutilization of dipeptidyl-4 inhibitors and alpha glucoside inhibitors, mostly due to unavailability of these medications in the formulary of the complex at the time of the study.

Efforts to control for blood pressure to the recommended level of 130 mmHg, systolic, and 80 mmHg, diastolic, have been achievable in only about one-third of the patients, despite the availability of varieties of antihypertensive drugs within the center. This inability to reduce blood pressure has also been observed in other institutes \[[@B28], [@B33]\]. The intensive control of blood pressure is still a debate in the literature as its benefit is small in the reduction of stroke compared to standard targets. Furthermore, the standards of diabetic care have raised the target systolic blood pressure from 130 mmHg to 140  mmHg \[[@B13], [@B28], [@B34]\]. The utilization of antihypertensive medications showed that most of subjects were on either ACE inhibitor or ARBs. No patients were on both medications as per SHMS guidelines \[[@B24]\]. The use of other classes of antihypertensive drugs in some subjects as monotherapy is probably due to a recent diagnosis of diabetes in addition to established hypertension, or coexisting problems of palpitation or anxiety symptoms, presence of coronary artery disease, or thyroid disorder. Thiazide is among the recommended diuretic combination therapy, yet the diuretics (indapamide or thiazide) were chosen with equal preference \[[@B34]\]. The availability of combined antihypertensive preparations (thiazide and ARBs in one tablet) at the center may explain the preference of diuretic compared to the low use of calcium channel blockers. Surprisingly, there was not a significant association between the clinical characteristics with monotherapy versus combination therapy among the samples. Further study with bigger sample size to test this association is needed.

The prescription practice of our sample population showed underutilization of the complete lipid profile test of diabetes management, particularly LDL. This practice can be accepted for cases with a previous cardiovascular event provided that they will receive statin therapy \[[@B13]\]. However, the underutilization of antilipid drugs (statins and fibrates) is marked in these patients despite their availability. Reducing LDL below a target level of 2.6 mmol/l is still difficult to attain in many populations including the US \[[@B9], [@B35]\]. The positive association of statin use with older age group in our study correlated positively with the current guidelines. These findings, together with high prevalence of obesity, stress the need for a clinical dietician in the complex \[[@B13]\].

Prescription of aspirin was seen at an earlier recommended age, that is, 50 years. This may be because of an increased awareness of the benefits of aspirin and following the old recommendation for the use of aspirin in the primary prevention of CVD \[[@B33], [@B36]\]. Interestingly, the lack of association of aspirin use among cases with dyslipidemia adds further need for proper management of dyslipidemia among diabetes management. Consistent with other studies, the primary prevention of CVD among type 2 diabetes patients is still an area of development \[[@B20]\].

Other areas that we found to be underutilized were fundus examinations and the health education clinic at the Al Imam Medical Complex. However, this result should be cautiously regarded since these patients are under shared care with other medical centers.

5. Conclusion {#sec5}
=============

This study investigated the prescription practice for a subpopulation of female patients with diabetes at a primary care center in Saudi Arabia. Our study revealed that the prescription practice for these female patients is consistent with standard diabetes care and SHMS guidelines. However, prescriptions for dyslipidemia still appear to be an area of attention in primary care. The utilization of insulin and incretins was expected to be higher among type 2 uncontrolled cases. This study had a small sample size and extrapolation of our results is limited. More importantly, this study sheds light on the trend of prescriptions practice for diabetes care and will help to draw attention, at the national level, for comprehensive diabetes care management with gender differences.
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###### 

Clinical characteristics of the study population (*n* = 160).

  Category                                                              Value (%)
  --------------------------------------------------------------------- ------------
  Age distribution, in years                                             
   11--20                                                               1 (0.6)
   21--30                                                               2 (1.3)
   31--40                                                               16 (10.0)
   41--50                                                               34 (21.3)
   51--60                                                               66 (41.3)
   \>60                                                                 31 (19.4)
  Nationality                                                            
   Saudi                                                                133 (83.1)
   Non-Saudi                                                            27 (16.9)
  Smoking history                                                        
   Unknown                                                              122 (76.3)
   Not smoking                                                          32 (23.8)
  Comorbid conditions                                                    
   Hypertension                                                         79 (49.4)
   Dyslipidemia                                                         72 (45.0)
   Thyroid disorder                                                     23 (14.4)
  Diabetic complications                                                 
   Retinopathy                                                          9 (5.6)
   Neuropathy                                                           6 (3.8)
   Stroke                                                               3 (1.9)
   Ischemic heart disease                                               1 (0.6)
  Blood pressure (mmHg)                                                  
   Systolic BP \> 130                                                   56 (35.0)
   Systolic BP ≥ 140                                                    39 (24.4)
   Diastolic BP \> 80                                                   33 (20.6)
  BMI (value), kg/m^2^                                                   
   Normal (18--25)                                                      3 (3)
   Overweight (25.1--29.9)                                              17 (16.8)
   Mild obesity (30--34.9)                                              33 (32.6)
   Moderate obesity (35--39.9)                                          40 (40)
   Morbid obesity (≥40)                                                 8 (8)
  Fundus examination                                                    49 (30.9)
  Health education                                                      48 (30.0)
  Laboratory results (*n* = number of participants that had the test)    
   HBA1c \>8.0 (*n* = 110)                                              23 (20.9)
   Serum creatinine \>135 umol/L (*n* = 70)                             None
   Albuminuria positive (*n* = 38)                                      5 (13.2)
   Cholesterol ≥ 5.2 mmol/L (*n* = 121)                                 37 (30.5)
  LDL ≥ 2.6 mmol/L (*n* = 94)                                           65 (69.2)
  HDL ≤ 1.3 mmol/L (*n* = 90)                                           58 (64.4)
  Triglyceride ≥ 1.7 mmol/L (*n* = 118)                                 14 (11.9)

###### 

Distribution of prescriptions for diabetes and cardiovascular management among the total study population.

  -----------------------------------------------------------------------------------------------------------------------
  Drug group according to clinical problem   Drug name                 Value (%) \                          Value (%) \
                                                                       (regardless of combination status)   monotherapy
  ------------------------------------------ ------------------------- ------------------------------------ -------------
  Drugs for hyperglycemia                    Metformin                 139 (86.9)                           55 (39.6)

  Sulphonylurea                              77 (48.1)                 6 (7.8)                              

  Pioglitazone                               23 (14.4)                 0                                    

  Insulin                                    23 (14.4)                 9 (39.1)                             

  Others \                                   5 (3.1)                   0                                    
  (acarbose, sitaglibtin)                                                                                   

  Total prescriptions                        267                       70                                   

                                                                                                            

  Antihypertensive drugs                     ACE inhibitors and ARBs   61 (38.1)                            38 (23.8)

  Diuretics \                                26 (16.2)                 5 (3.1)                              
  (thiazide + indapamide)                                                                                   

  B-blocker                                  21 (13.1)                 7 (33.3)                             

  Calcium channel blocker                    8 (5)                     1 (12.5)                             

  Total prescriptions                        124                       49                                   

                                                                                                            

  Lipid lowering agents                      Statin                    66 (41.3)                            64

  Others (fibrate, ezetimibe)                2                         0                                    

  Total prescription                         68                        64                                   

                                                                                                            

  Antiplatelets therapy                      Aspirin                   38 (23.8)                            35

  clopidogrel                                3                         0                                    

  Total prescriptions                        41                        35                                   
  -----------------------------------------------------------------------------------------------------------------------

###### 

Association of clinical characteristics with antidiabetic medications.

  Category                                     Antidiabetics                  
  -------------------------------------------- --------------- -------------- -------
  Number of patients (*n* = 155)               69              86              
  Age in years, mean (SD)                      50.8 (12.4)     55.6 (11.1)    0.020
  Systolic BP mmHg, mean (SD)                  116.9 (40.4)    118.5 (36.4)   0.793
  Diastolic BP mmHg, mean (SD)                 69.3 (22.8)     69.7 (23.1)    0.911
  BMI, mean (SD)                               33.2 (4.4)      34.0 (6.5)     0.480
  Hyperlipidemia, *n* value (%)                28 (40.6)       40 (46.5)      0.516
  Hypertension, *n* (%)                        38 (55.1)       41 (47.7)      0.420
  Thyroid disorder, *n* value (%)              12 (17.4)       10 (11.6)      0.358
  Diabetic complications^Ω^                    5 (7.2)         16 (18.6)      0.040
  HbA1c, mean (SD)                             5.9 ± 1.8       7.1 ± 2.2      0.006
  Cholesterol in mmol/L, mean (SD)             4.9 ± 0.8       4.7 ± 1.1      0.480
  Triglyceride in mmol/L, mean (SD)            1.4 ± 0.8       1.9 ± 1.5      0.161
  HDL in mmol/L, mean (SD)                     1.3 ± 0.3       1.2 ± 0.3      0.857
  LDL in mmol/L, mean (SD)                     3.4 ± 1.8       2.9 ± 0.9      0.096
  With health education visit, *n* value (%)   14 (20.3)       31 (36.0)      0.034
  With patient on antihypertensive drugs       19 (27.5)       31 (36.0)      0.100
  With patient on antilipid drugs              26 (37.7)       39 (45.3)      0.413
  With patient on antiplatelet                 14 (20.3)       24 (27.9)      0.348

\*Combination of four drugs: metformin + sulphonylure + actos + insulin.

^Ω^Diabetic complications: neuropathy + retinopathy + stroke + IHD + proteinuria. IHD: ischmic hear disease.
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